All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@_life_with_kaitlyn's compound semaglutide progress, fact-checked

_life_with_kaitlyn

TikTok creator

164.3K viewsWatch on TikTok→

Quick answer

The creator is using compounded semaglutide at a self-reported dose of 0.5mg, now on her eighth injection, and has lost 16.4 pounds since starting the medication. She attributes a slower week of one pound loss to menstrual cycle water retention, which is consistent with documented luteal phase fluid shifts. Her dosage language conflates insulin syringe units with milligrams, a common error with compounded injectables that warrants clarification from a prescribing clinician.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @_life_with_kaitlyn actually say?

Kaitlyn documents her eighth injection of compounded semaglutide and reports losing 29 pounds total, with 16.4 of those pounds coming since she started the medication. She's taking what she describes as "75 units at 0.5 milligrams" and losing an average of "two to two and a half pounds a week." This week she lost one pound, which she attributes to starting her menstrual cycle and the bloating that comes with it. She also shares injection technique observations, specifically that hitting a stretch mark hurts more than regular skin.

The video is a straightforward progress log, not a medical tutorial. She's not claiming semaglutide cures anything, and she's upfront that her weekly results vary. That transparency is worth noting because a lot of weight loss content on TikTok hides the slower weeks.

Does the science back this up?

Her average weight loss rate of two to two and a half pounds per week is on the higher end of what trials report, but not impossible, especially in earlier weeks. The bigger picture is more complicated than her numbers suggest.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, roughly 1.1 to 1.5 pounds per week when averaged out. Early weeks often show faster loss, partly from water weight and reduced caloric intake, before the rate levels off. Her claim of faster losses early on fits that pattern.

On the menstrual cycle affecting weight: this is real. Hormonal shifts in the luteal phase, specifically rising progesterone and estrogen fluctuations, cause water retention that can mask fat loss on the scale. A study by Bisdee et al. (1989, British Journal of Nutrition) documented cyclical weight fluctuations of one to two kilograms across the menstrual cycle. Kaitlyn is reading her body correctly here.

What did she get right, and what needs a closer look?

She gets credit for being honest about weekly variation. Most viral weight loss content cherry-picks the big weeks. She clearly states "I don't want everybody to think I have three and a half pounds of weight loss every week." That's responsible framing for a 164K-view video.

Her injection site advice, avoid stretch marks because it hurts more, is anecdotal and not clinically documented, but it's also not harmful advice. Injection site rotation is genuinely recommended to prevent lipohypertrophy, though the reason is tissue health, not pain reduction specifically.

The dosage description needs attention. She says "75 units at 0.5 milligrams." Semaglutide is not measured in insulin units. Units is insulin pen terminology. Compounded semaglutide is typically drawn in milliliters from a vial using an insulin syringe, where 75 units on the syringe corresponds to 0.75mL, not a fixed milligram dose, which depends entirely on the concentration of the compounded vial. This conflation of units and milligrams is a common point of confusion and worth flagging because it can lead to dosing errors.

What should you actually know?

Compounded semaglutide is not the same as FDA-approved Ozempic or Wegovy. The FDA has stated clearly that compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or manufacturing quality in the same way. The active ingredient may be semaglutide, but potency, sterility, and formulation can vary by pharmacy. This does not mean compounded versions are automatically unsafe, but it does mean the risk profile is different, and anyone using them should be working with a licensed prescriber who is monitoring their progress.

The STEP trials also used pharmaceutical-grade semaglutide at specific titrated doses. Extrapolating those results to compounded formulations is not scientifically supported. Results may be similar, or they may not be. There is no head-to-head trial data on this.

Weight loss during early menstrual cycle days is often masked by fluid retention and typically resolves within a few days. One pound in a week where you started your period is likely a reasonable week, not a bad one.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @_life_with_kaitlyn's compound semaglutide progress, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Claim verdict

The useful answer behind this video

Claim being checked

The creator is using compounded semaglutide at a self-reported dose of 0.

FormBlends verdict

The creator is using compounded semaglutide at a self-reported dose of 0.5mg, now on her eighth injection, and has lost 16.4 pounds since starting the medication. She attributes a slower week of one pound loss to menstrual cycle water retention, which is consistent with documented luteal phase fluid shifts. Her dosage language conflates insulin syringe units with milligrams, a common error with compounded injectables that warrants clarification from a prescribing clinician.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is using compounded semaglutide at a self-reported dose of 0.5mg, now on her eighth injection, and has lost 16.4 pounds since starting the medication. She attributes a slower week of one pound loss to menstrual cycle water retention, which is consistent with documented luteal phase fluid shifts. Her dosage language conflates insulin syringe units with milligrams, a common error with compounded injectables that warrants clarification from a prescribing clinician.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average semaglutide weight loss of 14.9% over 68 weeks, roughly 1.1 to 1.5 pounds per week on average. Early weeks can run faster.
  • Compounded semaglutide is not FDA-approved and has not been evaluated for safety or efficacy equivalence to Ozempic or Wegovy. The FDA has explicitly stated compounded drugs do not carry the same regulatory assurances.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average semaglutide weight loss of 14.9% over 68 weeks, roughly 1.1 to 1.5 pounds per week on average. Early weeks can run faster.
  • Compounded semaglutide is not FDA-approved and has not been evaluated for safety or efficacy equivalence to Ozempic or Wegovy. The FDA has explicitly stated compounded drugs do not carry the same regulatory assurances.
  • Menstrual cycle water retention in the luteal and early follicular phase can cause scale weight to increase by one to two kilograms, masking real fat loss (Bisdee et al., 1989, British Journal of Nutrition).
  • Describing semaglutide doses as 'units' is a terminology error. Units is insulin measurement language. Compounded semaglutide doses are drawn in milliliters, and the milligram amount depends on the specific compounded concentration.
  • GLP-1 receptor agonists reduce appetite and food preoccupation through hypothalamic pathways. The 'food noise' description is consistent with the drug's known mechanism, not just placebo effect.
  • Injection site rotation is clinically recommended to prevent lipohypertrophy, a buildup of fatty tissue that can impair drug absorption, not primarily for pain management.
  • Weekly weight loss will vary. Framing a one-pound week as a success, rather than a failure, is consistent with how bariatric clinicians interpret progress during hormonal fluctuations or plateaus.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

_life_with_kaitlyn · TikTok creator

164.3K views on this video

Shot 8! Compound Semaglutide! Cycle week! Still losing 💪🏻 #weightloss #weightlossprogress #cycleweek #semaglutide #glp1 #ozempic #wegovy #mounjaro #tirzepatide #compoundsemaglutide

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by _life_with_kaitlyn, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.